Welcome to our dedicated page for Dalrada Technology Group SEC filings (Ticker: DHTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SEC-related information and regulatory disclosures for Dalrada Technology Group, Inc. (DHTI), a multi-national holding company focused on technology, health care, and environmental sustainability. Although specific filings may vary over time, investors typically look to these documents to understand how Dalrada reports on its clean energy, semiconductor deposition, and health care activities.
Dalrada’s business segments include Dalrada Climate Technology, Deptec, and Genefic Specialty Pharmacy. In formal filings such as annual reports and quarterly reports, companies often describe segment operations, risks, and strategic priorities. For Dalrada, this can involve discussion of heat pump and energy sustainability technology, proprietary semiconductor deposition technology used for clean energy applications, and specialty pharmacy services with patient advocacy and support.
Stock Titan’s SEC filings page is designed to surface these documents as they are made available through EDGAR. Users can review key forms such as annual reports on Form 10-K and quarterly reports on Form 10-Q when filed, along with current reports on Form 8-K and other required submissions. For insider activity, Form 4 filings can provide detail on transactions by officers, directors, and certain shareholders.
AI-powered tools on this page help explain the contents of lengthy filings by summarizing important sections and highlighting notable disclosures related to Dalrada’s segments in clean energy, semiconductor deposition technology, and health care services. This can assist users who want to quickly identify how the company describes its operations, segment performance, and risk factors without reading every page of each filing.
Dalrada Technology Group reported continued losses and severe balance sheet weakness for the quarter ended December 31, 2025. Total revenue was $3.26 million, roughly flat versus the prior year’s $3.11 million, while six‑month revenue fell to $7.36 million from $9.15 million. Gross profit improved to $1.12 million in the quarter, but selling, general and administrative expenses of $4.70 million kept operations unprofitable, leading to a quarterly operating loss of $3.57 million and a six‑month net loss of $10.49 million.
The company’s financial position is strained. It ended the period with only $70,074 of cash and cash equivalents, total assets of $17.59 million, and total liabilities of $34.49 million, resulting in a stockholders’ deficit of $16.90 million. Management discloses negative working capital of $15.34 million and states there is “substantial doubt” about Dalrada’s ability to continue as a going concern without new financing and improved subsidiary performance.
Dalrada relies heavily on related‑party financing, with $8.58 million in related‑party payables and $4.64 million in related‑party notes payable, and has layered on multiple high‑cost loans and revenue purchase agreements. Operating cash outflows of $3.26 million in the first half of fiscal 2026 were covered only by $3.00 million of net cash from financing activities.
Dalrada Technology Group, Inc. filed a notification that it will be late submitting its quarterly report on Form 10-Q for the period ended December 31, 2025. The company states the filing delay is because it is in the final review process with its auditors and indicates the report will be filed within the standard grace period allowed. Dalrada also reports that all other required periodic reports over the past 12 months have been filed and that it does not anticipate any significant change in results of operations compared with the same period last year.
Dalrada Technology Group, through its subsidiary Genefic Inc., amended a prior report to clarify that new financing agreements create up to $25,000,000 in aggregate commitments, not $20,000,000 as first disclosed. The package combines up to $20,000,000 of standby letters of credit and related guarantees with a linked $5,000,000 revolving accounts receivable facility supporting Genefic’s healthcare operations.
The facilities run from December 31, 2025 to December 31, 2030 and are secured by first-priority liens on substantially all assets of Genefic and the parent company, plus a pledge of 100% of equity in all subsidiaries. Chairman and CEO Brian Bonar has provided an unlimited personal guaranty that is joint and several with the company’s obligations, and the board highlights resulting conflicts of interest between his personal exposure and his duties to shareholders. Upfront consideration includes $140,000 in cash, a $165,000 promissory note, and a pre-funded warrant valued at $225,000.
Dalrada Technology Group, through its wholly owned subsidiary Genefic Inc., entered into a financing structure providing up to
The arrangements are secured by first-priority liens on substantially all assets of Genefic and a first-priority security interest in substantially all assets of Dalrada, plus a pledge of 100% of the equity in all Dalrada subsidiaries. CEO Brian Bonar also provided an unlimited personal guaranty of Genefic’s obligations, which the Board identified as creating multiple potential conflicts of interest. Dalrada did not receive separate consideration for its upstream guarantee beyond benefits to Genefic.
Dalrada Technology Group, Inc. filed a current report to share that its Chief Executive Officer and Chairman, Brian Bonar, issued an open letter to shareholders dated January 20, 2026. The letter reviews the company’s 2025 performance, discusses operational progress in its core markets of renewable energy and heat pumps, atmospheric water generators, and semiconductor deposition solutions, and highlights recent partnerships, installations, and restructuring efforts. It also outlines Dalrada’s strategic focus and outlook for 2026 and beyond. The letter is included as Exhibit 99.1 and is furnished, rather than filed, under the securities laws.